InMed Pharmaceuticals Inc Share Price Deutsche Boerse AG
Equities
CA13764X1069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
05-14 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
05-14 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Sales 2024 * | 7.3M 5.32M 4.93M 419M | Sales 2025 * | 9.12M 6.65M 6.16M 524M | Capitalization | 2.43M 1.77M 1.64M 140M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.33 x |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 0.27 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.01% |
Latest transcript on InMed Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 15/06/16 |
Chief Operating Officer | - | 04/11/18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 10/02/22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 15/06/16 |
Andrew Hull
CHM | Chairman | 61 | 11/09/16 |
1st Jan change | Capi. | |
---|---|---|
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |